Author

Silvio Danese

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES
AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Silvio Danese  et al.

G-POEM FOR REFRACTORY GASTROPARESIS: BASAL SYMPTOM SEVERITY AND INTRAGASTRIC MEAL DISTRIBUTION DURING GASTRIC EMPTYING SCINTIGRAPHY MAY BE PREDICTORS OF 12-MONTH CLINICAL OUTCOME
G-POEM FOR REFRACTORY GASTROPARESIS: BASAL SYMPTOM SEVERITY AND INTRAGASTRIC MEAL DISTRIBUTION DURING GASTRIC EMPTYING SCINTIGRAPHY MAY BE PREDICTORS OF 12-MONTH CLINICAL OUTCOME

Silvio Danese  et al.

ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1? STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS
ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1? STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS

Silvio Danese  et al.

AN ARTIFICIAL INTELLIGENCE SYSTEM TO DETECT HISTOLOGICAL REMISSION AND PREDICT CLINICAL OUTCOMES IN ULCERATIVE COLITIS PATIENTS
AN ARTIFICIAL INTELLIGENCE SYSTEM TO DETECT HISTOLOGICAL REMISSION AND PREDICT CLINICAL OUTCOMES IN ULCERATIVE COLITIS PATIENTS

Silvio Danese  et al.

LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN TRUE NORTH WEEK 52 CLINICAL REMITTERS OVER 3 YEARS OF TREATMENT WITH OZANIMOD: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN TRUE NORTH WEEK 52 CLINICAL REMITTERS OVER 3 YEARS OF TREATMENT WITH OZANIMOD: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Silvio Danese  et al.

PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY
PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY

Silvio Danese  et al.

EFFICACY OF GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE NOT IN CLINICAL RESPONSE AT WEEK 12: RESULTS FROM THE GALAXI 1 STUDY
EFFICACY OF GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE NOT IN CLINICAL RESPONSE AT WEEK 12: RESULTS FROM THE GALAXI 1 STUDY

Silvio Danese  et al.

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY

Silvio Danese  et al.

PROPOFOL-BASED SEDATION MANAGED BY GASTROENTEROLOGIST VERSUS DEEP SEDATION DURING ENDOSCOPIC PROCEDURES IN LOW ANESTHESIOLOGICAL RISK PATIENTS (ASA I-II): A PROPENSITY SCORE-MATCHED COMPARISON IN A SINGLE TERTIARY CENTER
PROPOFOL-BASED SEDATION MANAGED BY GASTROENTEROLOGIST VERSUS DEEP SEDATION DURING ENDOSCOPIC PROCEDURES IN LOW ANESTHESIOLOGICAL RISK PATIENTS (ASA I-II): A PROPENSITY SCORE-MATCHED COMPARISON IN A SINGLE TERTIARY CENTER

Silvio Danese  et al.

ENDOSCOPIC SUBMUCOSAL DISSECTION IN SCARRED COLO-RECTAL LESIONS: A RETROSPECTIVE MULTICENTRIC STUDY WITH LONG-TERM FOLLOW-UP
ENDOSCOPIC SUBMUCOSAL DISSECTION IN SCARRED COLO-RECTAL LESIONS: A RETROSPECTIVE MULTICENTRIC STUDY WITH LONG-TERM FOLLOW-UP

Silvio Danese  et al.

EFFICACY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS BY BIOLOGIC INADEQUATE RESPONDER STATUS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES
EFFICACY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS BY BIOLOGIC INADEQUATE RESPONDER STATUS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES

Silvio Danese  et al.

PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY
PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

Silvio Danese  et al.

EFFICACY AND SAFETY OF UPADACITINIB AFTER 2 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
EFFICACY AND SAFETY OF UPADACITINIB AFTER 2 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)

Silvio Danese  et al.

HEALTH-RELATED QUALITY OF LIFE WITH GUSELKUMAB INDUCTION AND MAINTENANCE THERAPY AS MEASURED BY PROMIS-29: RESULTS THROUGH WEEK 48 OF PHASE 2 GALAXI 1 STUDY
HEALTH-RELATED QUALITY OF LIFE WITH GUSELKUMAB INDUCTION AND MAINTENANCE THERAPY AS MEASURED BY PROMIS-29: RESULTS THROUGH WEEK 48 OF PHASE 2 GALAXI 1 STUDY

Silvio Danese  et al.

DEFINING THE STANDARD LENGTH OF PERORAL ENDOSCOPIC MYOTOMY (POEM) FOR ACHALASIA: A SYSTEMATIC REVIEW AND METANALYSIS
DEFINING THE STANDARD LENGTH OF PERORAL ENDOSCOPIC MYOTOMY (POEM) FOR ACHALASIA: A SYSTEMATIC REVIEW AND METANALYSIS

Silvio Danese  et al.

OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY
OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Silvio Danese  et al.

HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY
HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY

Silvio Danese  et al.

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL

Silvio Danese  et al.

NEUTROPHIL-ONLY HISTOLOGICAL ASSESSMENT OF ULCERATIVE COLITIS CORRELATES WITH ENDOSCOPIC ACTIVITY AND PREDICTS LONG-TERM OUTCOMES IN A MULTICENTER STUDY
NEUTROPHIL-ONLY HISTOLOGICAL ASSESSMENT OF ULCERATIVE COLITIS CORRELATES WITH ENDOSCOPIC ACTIVITY AND PREDICTS LONG-TERM OUTCOMES IN A MULTICENTER STUDY

Silvio Danese  et al.

DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE
DUAL TARGETED THERAPY: A FUTURE STRATEGY FOR THE MANAGEMENT OF REFRACTORY INFLAMMATORY BOWEL DISEASE

Silvio Danese  et al.

Item 121 - 140 / 148
1 2 3 4 5 6
7
8